ライフサイエンスコーパス: rosiglitazone

1 % of the activation of the positive control (rosiglitazone).

2 reatment of mice with the insulin sensitizer rosiglitazone.

3 ator-activated receptor gamma sensitivity to rosiglitazone.

4 tures were treated with the PPARgamma ligand rosiglitazone.

5 sly reported amorfrutins, similar to that of rosiglitazone.

6 e loss side effect of the PPAR-gamma agonist rosiglitazone.

7 types may be different for pioglitazone and rosiglitazone.

8 ytes was increased by the anti-diabetic drug rosiglitazone.

9 edema side effects of the PPARgamma agonist rosiglitazone.

10 erent from metformin alone or metformin plus rosiglitazone.

11 sis by AFC was also attenuated compared with rosiglitazone.

12 ion (miR-98 mimic), or the PPARgamma agonist rosiglitazone.

13 e-proliferator-activated receptor-gamma with rosiglitazone.

14 roliferator-activated receptor-gamma agonist Rosiglitazone.

15 activated receptor-gamma (PPARgamma) ligand, rosiglitazone.

16 different from responses induced by the TZD rosiglitazone.

17 c acid (13-HODE) and thiazolidinedione (TZD)-rosiglitazone.

18 creased mainly in women randomly assigned to rosiglitazone.

19 ta was also up-regulated by pioglitazone and rosiglitazone.

20 effect profile compared to the full agonist rosiglitazone.

21 d) in the presence of the PPARgamma agonist, rosiglitazone.

22 played iWAT browning, even in the absence of rosiglitazone.

23 an the median expected percentage prescribed rosiglitazone.

24 ly, down-regulated by the anti-diabetic drug rosiglitazone.

25 gonists such as TZD diabetes drugs including rosiglitazone.

26 t but also impairs the anti-tumor effects of rosiglitazone.

27 ates the anti-tumor effects of PPARgamma and rosiglitazone.

28 ) or without (n = 8) the anti-diabetes drug, rosiglitazone.

29 weight and with effectiveness comparable to rosiglitazone.

30 , is reversed by the upregulation of NRF2 by rosiglitazone.

31 agonize the effects of the PPARgamma agonist rosiglitazone.

32 alter the activity of the anti-diabetic drug rosiglitazone.

33 Supplementing the diet with rosiglitazone (1.5 mg/g body weight) for an additional 4

34 ted for 7 days with metformin (10 mM) and/or rosiglitazone (10 muM).

35 Activation of PPARgamma by Rosiglitazone (10 uM) reversed the LPS-mediated effects

36 endently up-regulated IGF-1R protein levels (rosiglitazone, 10 mumol/liter, 67% increase, n = 4, p <

37 ollows: 1) metformin (100 mg/kg per day), 2) rosiglitazone (2 mg/kg per day), and 3) no drug.

38 sistance were randomized to rhGH 3 mg daily, rosiglitazone 4 mg twice daily, combination rhGH + rosig

39 etformin alone or to metformin combined with rosiglitazone (4 mg twice a day) or a lifestyle-interven

40 signed to receive either 4 mg twice-daily of rosiglitazone, 4 mg of rosiglitazone and 500 mg of metfo

41 to the known insulin-sensitizing effects of rosiglitazone (6 mg kg(-1) day(-1) ).

42 Although less proadipogenic than rosiglitazone, 7j significantly increases adipocyte insu

43 7 days with metformin (250 mg/kg/day) and/or rosiglitazone (8 mg/kg/day).

44 Rosiglitazone, a blood-brain barrier-impermeant PPARgamm

45 In our type 2 diabetes/obesity model, rosiglitazone, a peroxisome proliferator-activated recep

46 tment of selenium-deficient macrophages with rosiglitazone, a peroxisome proliferator-activated recep

47 Rosiglitazone, a peroxisome proliferator-activated recep

48 Here we show that rosiglitazone, a PPAR-gamma agonist, rescued the dendrit

49 egulation by TNFalpha, which was reversed by rosiglitazone, a result consistent with altered high man

50 tion or when mice were treated for 1 wk with rosiglitazone, a specific agonist of peroxisome prolifer

51 Rosiglitazone, a specific peroxisome proliferator-activa

52 Recent studies have associated rosiglitazone, a thiazolidinedione drug, with adverse ca

53 Rosiglitazone, a well known insulin sensitizer, stimulat

54 roliferator-activated receptor-gamma agonist rosiglitazone abrogated diet-induced mammary growth.

55 The addition of rosiglitazone abrogated the adverse effects of rhGH on i

56 that ped/pea-15 repression may contribute to rosiglitazone action on glucose disposal.

57 down-regulation, whereas metformin reversed rosiglitazone activity at the translational level.

58 10-fold) treatment, or the antidiabetic drug rosiglitazone, all known PPAR activators.

59 glitazone and -22.7% in rhGH) but not in the rosiglitazone alone (-2.5%) or control arms (-1.9%).

60 and losartan confers no greater benefit than rosiglitazone alone with respect to histopathology.

61 rsus rosiglitazone and losartan, compared to rosiglitazone alone, after 48 weeks of therapy.

62 The insulin-sensitizing drug rosiglitazone also increases the expression of CTRP13 in

63 adverse effect, and long-term treatment with rosiglitazone altered liver enzymes and caused hepatic f

64 5 expression and caused nonresponsiveness to rosiglitazone, although c-jun overexpression enhanced th

65 insulin doses, protection was potentiated by rosiglitazone, an insulin-sensitizing drug used to treat

66 gnificantly in the rhGH arms (-17.5% in rhGH/rosiglitazone and -22.7% in rhGH) but not in the rosigli

67 r 4 mg twice-daily of rosiglitazone, 4 mg of rosiglitazone and 500 mg of metformin twice-daily, or 4

68 Supplementing with PPARgamma agonists rosiglitazone and GW1929 was sufficient to restore M2 di

69 dipose tissue remodeling similar to those of rosiglitazone and had enhanced antiinflammatory effects.

70 following exposure to the anti-diabetic drug rosiglitazone and increased circulating levels in adipon

71 therapy with rosiglitazone and metformin or rosiglitazone and losartan confers no greater benefit th

72 litazone and metformin in combination versus rosiglitazone and losartan, compared to rosiglitazone al

73 en-label trial was to assess the efficacy of rosiglitazone and metformin in combination versus rosigl

74 orty-eight weeks of combination therapy with rosiglitazone and metformin or rosiglitazone and losarta

75 igate the effects of two antidiabetic drugs, rosiglitazone and metformin, on PepT1 activity/expressio

76 by anti-diabetic PPARgamma ligands, such as rosiglitazone and MRL24.

77 PPARgamma agonists such as rosiglitazone and pioglitazone are in clinical use for t

78 Microarray analysis revealed that while rosiglitazone and pioglitazone had little effect on gene

79 Compound 6 exhibited comparable efficacy to rosiglitazone and pioglitazone in vivo.

80 some proliferator-activated receptor ligands rosiglitazone and pioglitazone inhibited CYP26A1 with IC

81 Whereas rosiglitazone and pioglitazone potentiated cell death, t

82 Thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone, are peroxisome prolifera

83 ects of thiazolidinediones (TZDs), including rosiglitazone and pioglitazone, on cardiac tissue.

84 We tested the effect of two TZD class drugs, rosiglitazone and pioglitazone, on human aortic smooth m

85 (TZD) class of antidiabetes drugs including rosiglitazone and pioglitazone.

86 ceptor phosphorylation, and this response to rosiglitazone and possibly to pioglitazone was PPARgamma

87 We used rosiglitazone and primary adipocytes to stringently eval

88 These compounds were far better than rosiglitazone and the other isolated compounds in enhanc

89 termine, L-phenylepherine, proglitazone, and rosiglitazone) and seven interferences chosen from off-t

90 duced CH, mice were fed a high-fat diet with rosiglitazone, and cardiac and metabolic consequences we

91 of 234) for metformin alone, metformin plus rosiglitazone, and metformin plus lifestyle intervention

92 ction and insulin sensitivity over time with rosiglitazone appear to be responsible for its superior

93 in resistance, and PPARgamma ligands such as rosiglitazone are insulin sensitizing, yet the mechanism

94 lts suggest that the behavioral responses to rosiglitazone are mediated through PPARgamma-dependent i

95 approved thiazolidinediones pioglitazone and rosiglitazone are peroxisome proliferator-activated rece

96 for human psoriasis, that is, Etanercept and Rosiglitazone, are effective in alleviating the symptoms

97 Using rosiglitazone as a model PPARgamma agonist, which decrea

98 used the facility proportion of patients on rosiglitazone as the predictor (instrumental variable ap

99 In this study, we show that, in L6 cells, rosiglitazone- as well as pioglitazone-dependent activat

100 Rosiglitazone attenuated bleomycin-induced skin inflamma

101 hereas treatment with the insulin sensitizer rosiglitazone attenuated both metabolic syndrome and ath

102 In addition, administering ACSL4 inhibitor rosiglitazone before ischemia diminished the ferroptotic

103 the adiponectin production was prevented by rosiglitazone but not by antioxidants.

104 th AFC improved glucose tolerance similar to rosiglitazone, but AFC did not promote weight gain to th

105 The addition of rosiglitazone, but not an intensive lifestyle interventi

106 Treatment by the PPARgamma ligand rosiglitazone, but not PI3K modulators, rescued colorect

107 For colorectal cancer, rosiglitazone, but not pioglitazone, was associated with

108 ype mice with LPS and the PPARgamma agonist, rosiglitazone, but not the PPARalpha agonist (WY-14643),

109 metabolism genes in the heart was altered by rosiglitazone, but these changes were not attenuated by

110 treatment of mice with the PPARgamma agonist rosiglitazone caused a greater improvement in in vivo in

111 into adipocytes using the PPARgamma agonist rosiglitazone combined with the MEK inhibitor trametinib

112 The adjusted hazard ratio for rosiglitazone compared with pioglitazone was 1.06 (95% c

113 vents per 100 person-years of treatment with rosiglitazone compared with pioglitazone.

114 nd mortality associated with prescription of rosiglitazone, compared with other oral hypoglycemic age

115 Rosiglitazone deactivated the mitogen-activated protein

116 roliferator-activated receptor gamma agonist rosiglitazone decreased activator protein 1 promoter act

117 MC neurons induced by the PPAR-gamma agonist rosiglitazone decreased ROS levels and increased food in

118 Rosiglitazone did not affect LV remodeling, increased pe

119 In control mice, rosiglitazone did not alter plasma aldosterone levels or

120 Injection of rosiglitazone directly into the tibiotarsal joints of B.

121 ny possible effect on myocardial infarction, rosiglitazone does not increase the risk of overall card

122 Rosiglitazone-driven adipogenic differentiation of both

123 nal assays in hiPSC-CMs using tacrolimus and rosiglitazone, drugs targeting pathways predicted to pro

124 g to the ped/pea-15 promoter and blocked the rosiglitazone effect.

125 Rosiglitazone effects on cdc42 activation and Caco-2 ShP

126 lormethiazide, but not amiloride, attenuated rosiglitazone effects on volume expansion and CH.

127 The PPAR-gamma agonist rosiglitazone elicited similar changes in macrophage cyt

128 Rosiglitazone enhanced insulin-induced glucose uptake in

129 The cardiovascular effects of rosiglitazone for patients with coronary artery disease

130 tive pathway and the increased inhibition by rosiglitazone G confirmed the sensitivity of the bacteri

131 vity of AasC was sensitive to triacsin C and rosiglitazone G.

132 spital or death occurred in 61 people in the rosiglitazone group and 29 in the active control group (

133 321 people in the rosiglitazone group and 323 in the active control group

134 Mean HbA(1c) was lower in the rosiglitazone group than in the control group at 5 years

135 ral hypoglycemic agents, patients prescribed rosiglitazone had significantly higher all-cause (hazard

136 atients who had diabetes and were prescribed rosiglitazone had significantly higher all-cause mortali

137 Rosiglitazone has no effect on chloride secretion in the

138 In contrast, rosiglitazone has no effect on ENaC activity.

139 ed PPARgamma full agonists, pioglitazone and rosiglitazone, have been reported to produce serious adv

140 , but activates GLUT4 to a similar degree as rosiglitazone, implying gene-specific partial agonism.

141 Rosiglitazone improves glycemic control for patients wit

142 activated receptor-gamma (PPARgamma) agonist rosiglitazone improves hippocampus-dependent cognitive d

143 at retains similar anti-diabetic efficacy as rosiglitazone in mice yet does not elicit weight gain or

144 ells induced by a specific PPARgamma agonist rosiglitazone in mice.

145 king pose similarity between telmisartan and rosiglitazone in PPAR gamma active site, two classes of

146 Administration of rosiglitazone in T1DM-2W mice up-regulated the expressio

147 two insulin-sensitizing drugs (metformin and rosiglitazone) in a genetic model of spontaneously hyper

148 lta12,14-prostaglandin J2, troglitazone, and rosiglitazone) in cat corneal fibroblasts.

149 of the glitazone scaffold, pioglitazone and rosiglitazone, in an effort to identify off-target bindi

150 Similarly, rosiglitazone increased miR-98 and reversed nicotine-ind

151 The PPARgamma agonist rosiglitazone increases insulin sensitivity and is effec

152 These results suggest that rosiglitazone increases PHD expression in a PPARgamma-de

153 reviously, we reported that pioglitazone and rosiglitazone induce osteocyte apoptosis and sclerostin

154 phosphorylated at serine 112 but had reduced rosiglitazone-induced activity at lipogenic genes.

155 (PHD) levels significantly increased during rosiglitazone-induced adipocyte differentiation (RIAD).

156 PARgamma-selective antagonist GW9662 blocked rosiglitazone-induced adiponectin expression and antidep

157 Here we show that rosiglitazone-induced browning of human adipocytes activ

158 tor in human adipocytes that is required for rosiglitazone-induced browning, including the increase i

159 etic furosemide in wild-type mice attenuated rosiglitazone-induced CH, hypertrophic gene reprogrammin

160 esis that volume expansion directly mediates rosiglitazone-induced CH, mice were fed a high-fat diet

161 in the collecting duct, but still exhibited rosiglitazone-induced fluid retention.

162 iglitazone, Pparg-BKO mice were resistant to rosiglitazone-induced hyperphagia and weight gain and, r

163 al triglyceride accumulation relative to the rosiglitazone-induced maximum.

164 d not modify PepT1 activity but counteracted rosiglitazone-induced PepT1-mediated transport.

165 suppressed PPARgamma expression and blocked rosiglitazone-induced pre-adipocyte differentiation towa

166 2 demonstrated this residue as essential for rosiglitazone-induced receptor activation, but nonessent

167 owed loss of PPARgamma and were resistant to rosiglitazone-induced WAT differentiation.

168 receptor gamma (PPARgamma) agonists such as rosiglitazone induces browning of rodent and human adipo

169 Pretreatment with rosiglitazone inhibited the Ang II-induced expression of

170 Both pretreatment and posttreatment with rosiglitazone inhibited the occurrence of fatal rupture

171 Ten-day rosiglitazone injection not only improved the response t

172 There was no significant rhGH x rosiglitazone interaction for any body composition param

173 Rosiglitazone is an insulin sensitiser used in combinati

174 The use of pioglitazone and rosiglitazone is associated with a decreased liver cance

175 As rosiglitazone is clinically used to treat diabetes, our

176 uction of lesions in animals pretreated with rosiglitazone is concomitant with decreased expression o

177 ARgamma phosphorylation in obese patients by rosiglitazone is very tightly associated with the anti-d

178 e activity could be enhanced by lanthanum or rosiglitazone, known stimulators of TRPC5 and TRPC5-cont

179 owever, in subcutaneous inguinal fat (iWAT), rosiglitazone markedly induced molecular signatures of b

180 Studies have suggested that the use of rosiglitazone may be associated with an increased risk o

181 er region of PHDs by ChIP-PCR, implying that rosiglitazone may induce PHD up-regulation directly by P

182 PPAR-gamma agonists, such as rosiglitazone, may therefore be effective treatments for

183 Importantly, rosiglitazone-mediated whole-body metabolic improvements

184 were treated for a median of 4.0 years with rosiglitazone, metformin, or glyburide and were examined

185 able adjustment, among patients treated with rosiglitazone, mortality was similar (hazard ratio [HR],

186 spanic black participants and metformin plus rosiglitazone most effective in girls.

187 f 7.9% were randomly assigned to addition of rosiglitazone (n=2220) or to a combination of metformin

188 oliferator-activated receptor-gamma) agonist rosiglitazone, Noc expression was enhanced 30-fold.

189 rse trophoblast-associated inflammation with Rosiglitazone offers promise that the PPARgamma - NF-kap

190 PP5 are resistant to the negative effects of rosiglitazone on bone, which in wild type animals causes

191 ation of IGF-1R, we determined the effect of rosiglitazone on oxidized LDL (oxLDL)-induced apoptosis.

192 idyl ether or GW9662) blunted the effects of rosiglitazone on PHD regulation.

193 el, separate treatment of hyperglycemia with rosiglitazone or hypertension with lisinopril partially

194 oglitazone use adjusted for sex, age, use of rosiglitazone or metformin, and cardiovascular comorbidi

195 ncomitant inhibition of NF-kappaB (either by Rosiglitazone or NF-kappaB specific inhibitor), revealin

196 Moreover, treatment with rosiglitazone or pioglitazone did not significantly alte

197 ge, 74.4 years) who initiated treatment with rosiglitazone or pioglitazone through a Medicare Part D

198 show that treatment with PPARgamma agonists (rosiglitazone or pioglitazone) in primary cultures of mo

199 toneal administration of PPARgamma agonists (rosiglitazone or pioglitazone).

200 er cancer incidence was found for any use of rosiglitazone (OR: 0.73, 95% CI: 0.65-0.81) or pioglitaz

201 Treating epithelial cells with synthetic (rosiglitazone) or endogenous (10-nitro-oleic acid) PPARg

202 However, when Ucp1 was activated by rosiglitazone, or by iWAT browning in cold-exposed or yo

203 Treatment with pioglitazone, rosiglitazone, or dexamethasone significantly protected

204 itazone 4 mg twice daily, combination rhGH + rosiglitazone, or double placebo (control) for 12 weeks.

205 inhibitor phloridzin, the insulin-sensitizer rosiglitazone, or insulin.

206 ds repress Retn transcription in adipocytes, rosiglitazone paradoxically stimulates the enhancer acti

207 nt mice with the synthetic PPAR-gamma ligand rosiglitazone partially normalizes the altered gene expr

208 Background Thiazolidinediones (rosiglitazone, pioglitazone) are oral insulin-sensitizin

209 All three PPARgamma ligands (rosiglitazone, pioglitazone, and 15-deoxy-Delta(12,14)-p

210 Pioglitazone and rosiglitazone possess a common functional core, glitazon

211 In the presence of rosiglitazone, PP5 translocates to the nucleus, binds to

212 When treated with the TZD rosiglitazone, Pparg-BKO mice were resistant to rosiglit

213 lta(12,14)-prostaglandin J(2)) or synthetic (rosiglitazone) PPARgamma ligands enhanced B cell prolife

214 planted fibroblasts and skin organ cultures, rosiglitazone prevented the stimulation of collagen gene

215 -term treatment with metformin, but not with rosiglitazone, prevents the development of severe CHF in

216 Both nitrite and rosiglitazone produced improvements, relative to saline,

217 ) demonstrated that initial monotherapy with rosiglitazone provided superior durability of glycemic c

218 ses of bexarotene with the PPARgamma agonist rosiglitazone provides effective growth suppression of m

219 20 mumol/liter of rosiglitazone reduced oxidized LDL-induced apoptosis by

220 erentiation induced by the PPARgamma agonist rosiglitazone, reduced obesity development and ameliorat

221 Remarkably, rosiglitazone restored insulin secretion in response to

222 e, PPARgamma activation (i.e. treatment with rosiglitazone) restored euglycemia and reversed high fat

223 ation of human aortic endothelial cells with rosiglitazone resulted in the time- and dose-dependent s

224 Treatment with the PPAR-gamma agonist rosiglitazone reversed the phenotype.

225 Here, rosiglitazone (RGZ) activation of GPR40 and p38 MAPK was

226 The insulin sensitizing glitazone drugs, rosiglitazone (ROS) and pioglitazone (PGZ) both have ant

227 h the individual-specific effects of the TZD rosiglitazone (rosi) on gene expression.

228 tivated Receptor gamma (PPARgamma) activator rosiglitazone (Rosi) or prostaglandin E2 analog (16,16-d

229 We found that rosiglitazone (Rosi) significantly improved insulin sens

230 or (PPARgamma) ligands pioglitazone (Pio) or rosiglitazone (Rosi) to TGF-beta-treated orbital fibrobl

231 liferation-activated receptor-gamma agonist, rosiglitazone (Rosi), a medication recently reintroduced

232 ted for type II diabetes treatment; however, rosiglitazone (ROSI), a PPARgamma agonist, increases foo

233 utic potential of this pathway, we examined, rosiglitazone (Rosi), a PPARgamma agonist, which has bee

234 to DMSO vehicle, the pharmaceutical obesogen rosiglitazone (ROSI), or TBT (5.42, 54.2, or 542 nM) thr

235 stimulating cells with the PPARgamma agonist rosiglitazone (Rosi).

236 ompared to the multi-billion dollar TZD drug rosiglitazone (Rosi).

237 rator-activated receptor (PPAR)gamma agonist rosiglitazone (RSG) but the consequence of this interact

238 activated receptor gamma (PPARgamma) agonist rosiglitazone (RSG) improved hippocampus-dependent cogni

239 The PPARgamma agonist rosiglitazone (RSG) promoted quiescence in the activated

240 term labor and that PPARgamma activation via rosiglitazone (RSG) would attenuate the macrophage-media

241 gonists currently in clinical use, including rosiglitazone (RSG), are often associated with severe si

242 conclude that mesalamine, sulfasalazine, and rosiglitazone significantly reduced the cellular express

243 Stimulation of PPAR-gamma in vivo (rosiglitazone) significantly attenuates biliary damage a

244 ive capacity are maintained independently of rosiglitazone, suggesting that additional browning facto

245 f this NOC-peptide was partially reversed by rosiglitazone, suggesting that effect of NOC on PPAR-gam

246 accumulation compared with that triggered by rosiglitazone, suggesting that LT175 may have a lower ad

247 R3) counteracted this rescue, suggesting the rosiglitazone survival effect was, at least in part, med

248 Moreover, upon coadministration with rosiglitazone, T2384 was able to antagonize the side eff

249 prevented by suramin, a PTP1B inhibitor, or rosiglitazone that decreased PTP1B levels.

250 ed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compar

251 y-resistant and -sensitive mice treated with rosiglitazone to generate candidate brite biomarkers fro

252 Addition of rosiglitazone to glucose-lowering therapy in people with

253 ce, an effect associated with the failure of rosiglitazone to improve liver insulin receptor signal t

254 FP407 was required for the PPARgamma agonist rosiglitazone to increase Glut4 expression, but was not

255 ith in vitro results, oral administration of rosiglitazone to ob/ob mice for 2 weeks increased adipos

256 We aimed to determine if adding rosiglitazone to rhGH would abrogate the adverse effects

257 hyperphagia and weight gain and, relative to rosiglitazone-treated Pparg(f/f) mice, experienced only

258 le to antagonize the side effects induced by rosiglitazone treatment alone while retaining robust eff

259 Collectively, these results indicate that rosiglitazone treatment attenuates inflammation, dermal

260 se in hepatic insulin sensitivity induced by rosiglitazone treatment during HFD feeding was completel

261 duced insulin-resistant mice and improved by rosiglitazone treatment in the latter.

262 A 7-day rosiglitazone treatment increased PepT1 activity and pre

263 Rosiglitazone treatment induced volume expansion and CH

264 ternal-fetal interface and systemically, and rosiglitazone treatment partially attenuated these respo

265 In these experiments, rosiglitazone treatment reduced c-JUN presence at the PE

266 Rosiglitazone treatment reduced the induction of the ear

267 Rosiglitazone treatment restored insulin sensitivity in

268 logical concentrations of Adn resulting from rosiglitazone treatment suppressed regeneration by reduc

269 As with the in vivo studies, rosiglitazone treatment up-regulated PepT1 transport act

270 matched analysis supported an association of rosiglitazone treatment with an increase in major ischem

271 ted receptor (PPAR)gamma activation, through rosiglitazone treatment, reduced the rate of alpha-GalCe

272 Furthermore, rosiglitazone treatment, which promotes redistribution o

273 vels, although these effects were reduced by rosiglitazone treatment.

274 ckdown of PP5 results in cells refractory to rosiglitazone treatment.

275 espectively; this suppression was rescued by rosiglitazone treatment.

276 All of these effects were blunted after rosiglitazone treatment.

277 Herein, we show that PPARgamma ligands (rosiglitazone, troglitazone, and 15-deoxy-Delta12,14-pro

278 y distinct PPARgamma agonists [pioglitazone, rosiglitazone, troglitazone, and 15-deoxy-Delta12,14-pro

279 500 mg of metformin twice-daily, or 4 mg of rosiglitazone twice-daily and 50 mg of losartan once-dai

280 eptor (PPAR) gamma agonists pioglitazone and rosiglitazone up-regulated CYP26B1 transcription by as m

281 tic agonists of PPAR-gamma (pioglitazone and rosiglitazone) up-regulates PPAR-gamma-dependent genes,

282 To examine any association between rosiglitazone use and cardiovascular events among patien

283 findings suggest significant associations of rosiglitazone use with higher cardiovascular and all-cau

284 showed more favorable changes over time with rosiglitazone versus metformin or glyburide.

285 ars of follow-up among patients treated with rosiglitazone versus patients not receiving a thiazolidi

286 rescription of pioglitazone, prescription of rosiglitazone was associated with an increased risk of s

287 ve to saline and rosiglitazone, whereas only rosiglitazone was effective at reducing hepatic glucose

288 Rosiglitazone was given 1 week before infusion and 1 wee

289 Inhibition of follistatin expression by rosiglitazone was not associated with decreased follista

290 Metformin plus rosiglitazone was superior to metformin alone (P=0.006);

291 A novel effect of rosiglitazone was to increase expression of Nrf2 (nuclea

292 Rosiglitazone was used as a positive control.

293 rotic process in vivo, the synthetic agonist rosiglitazone was used in a mouse model of scleroderma.

294 known PPARgamma ligands (MDG548, GW1929, and rosiglitazone), we have designed and synthesized azobenz

295 These effects of rosiglitazone were absent in mice lacking adiponectin bu

296 lthough the maximal efficacies of INT131 and rosiglitazone were similar with respect to improvements

297 owered blood pressure relative to saline and rosiglitazone, whereas only rosiglitazone was effective

298 re, the combination of the PPARgamma agonist rosiglitazone with bexarotene synergistically suppressed

299 AFC activated PPARgamma as effectively as rosiglitazone with regard to Adrp, Angptl4, and AdipoQ,

300 The hypothesis that rosiglitazone would reduce aneurysm expansion or rupture